MustGrow Biologics Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of MustGrow Biologics Corp. generated cash of -$294,764, which is more than the previous year. Cash used in financing activities reached the amount of $95,750 last year. Net change in cash is therefore -$199,014.
Cash Flow
| 2016 | -2.56K | 0 | 0 |
|---|---|---|---|
| 2017 | -6.74K | -175K | 198.11K |
| 2018 | -968.34K | 0 | 1.46M |
| 2019 | -1.35M | 0 | 4.87M |
| 2020 | -2.57M | 0 | 1.86M |
| 2021 | -2.41M | 0 | 8.71M |
| 2022 | -3.25M | 0 | 653.75K |
| 2023 | -294.76K | 0 | 95.75K |
MGRO.V Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 7.01M | 9.61M | 3.31M | 4.02M | 507.32K | 7.15K | 937 | 1 |
Operating activities | ||||||||
Net income | -676.94K | -5.56M | -3.06M | -3.30M | -1.51M | -1.89M | -36.45K | -20.44K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 926.42K | 1.69M | 270.81K | 776.90K | 124.78K | 0 | 0 | 0 |
| Deferred income tax benefit | 926.42K | 1.69M | 270.81K | 776.90K | 124.78K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | -23.49K | -31.02K | -12.99K | 5.54K | 0 | -510 | 0 |
Inventories | 0 | 297.27K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | -273.78K | 351.24K | 44.92K | -4.23K | 0 | 58.89K | 0 |
Cash generated by operating activities | -294.76K | -3.25M | -2.41M | -2.57M | -1.35M | -968.34K | -6.74K | -2.56K |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | -175K | 0 |
Financing activities | ||||||||
Common Stock Issued | 95.75K | 653.75K | 6.58M | 1.86M | 4.80M | 1.46M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 175K | 0 |
Cash used in financing activities | 95.75K | 653.75K | 8.71M | 1.86M | 4.87M | 1.46M | 198.11K | 0 |
Net Change In Cash | -199.01K | -2.60M | 6.30M | -716.01K | 3.52M | 500.17K | 16.37K | 3.50K |
Cash at end of period | 6.81M | 7.01M | 9.61M | 3.31M | 4.02M | 507.32K | 17.31K | 3.50K |